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Abstract: UNLABELLED The optimum treatment for differentiated thyroid carcinoma (DTC) is still
debated. Results obtained using a selective treatment strategy for papillary (PTC) and follicular (FTC)
thyroid carcinoma over 25 years in one institution are reported. 149 patients (mean age 46 yrs) had
PTC in TNM stages I-IV in 58%, 26%, 15% and 1% respectively. Total thyroidectomy and remnant 131I
ablation (43%) were carried out in TNM high-risk patients (stages III and IV) and in low-risk patients (I
and II) at risk for a (curable) recurrence (stages pN1 and/or pT4). Hemi- or total thyroidectomy, without
radioiodine, was used in 76% of pT1-3 N0 tumours (68%). Central and/or lateral lymphadenectomy was
performed in 42% of patients (electively in the last 4 years). The mean follow-up was 7 years. RESULTS
6 patients died of PTC and 8/143 patients treated for cure had a recurrence (6 nodal, 1 contralateral,
1 local). In low-risk patients–including 68% of patients aged > or = 45 yrs–the cause specific 25-year
survival rate was 100%, vs. 62% (at 15 years) (p < 0.0001) in high-risk patients. In stage I and stage II
the recurrence-free survival rates at 25 years were 95% and 100% respectively. Risk factors for recurrence
were macroscopic (p < 0.0001) but not microscopic local invasion (pT4); stage pN1 (p = 0.0004). Only
1/107 patients initially judged node-negative had a nodal recurrence. FTC (n = 115; mean age 56 yrs;
mean follow-up 8 yrs): Cause-related death (n = 8) or serious recurrence (n = 3) occurred in 10/53
grossly invasive FTC, in 1/45 minimally invasive FTC with vascular invasion, and in none of 17 FTC
with capsular invasion (CI) alone, under radical treatment (131I) in 75%, 33%, and 12% respectively.
20-year disease-free survival in grossly and in minimally invasive FTC was 78% and 95.5% respectively
(p = 0.0007). Patients aged < 45 yrs and patients with minimally invasive FTC with CI alone (all
ages) had 100% 20-year disease-free survival vs. 80% (p = 0.013) in the remainder. There was no
curable recurrence in FTC. The ratio of grossly invasive FTC decreased (p < 0.0001) during the study
period. CONCLUSIONS Risk-0 groups may be defined and selected for a reduced extent of treatment
(PTC pT1-3 N0; FTC < 45 yrs, or CI alone). Older (> or = 45 yrs) patients with PTC in stages I
and II have an excellent prognosis (risk 0). With selective (therapeutic) lymphadenectomy the risk of
nodal recurrence may be very low in node negative tumours, without use of radioiodine. Meticulous
lymphadenectomy is indicated in pN1 tumours with nodal recurrences despite 131I (5/36 patients). The
technique of capsular dissection for extracapsular total uni- or bilateral thyroidectomy provides excellent
oncological and surgical results. A decrease in the incidence of FTC parallels a decrease in endemic goitre
in Switzerland.
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Differentiated thyroid carcinomas (DTC) are
biologically unique tumours. Prognostic classifica-
tions serve to segregate a majority of patients with
near-0 risk of tumour-related death from a minor-
ity at much greater risk [1–8]. Major risk factors
are patient’s age, tumour size, grade, extent (inva-
sion) (pT4), metastases (M1), and completeness of
resection for papillary (PTC), and invasiveness for
follicular (FTC) thyroid carcinoma [9–14]. Several
prognostic classification systems based upon these
factors (AGES, AMES, MACIS, age-related
TNM classification) [1, 2, 5, 13, 15] have proven
The optimum treatment for differentiated
thyroid carcinoma (DTC) is still debated. Results
obtained using a selective treatment strategy for
papillary (PTC) and follicular (FTC) thyroid car-
cinoma over 25 years in one institution are re-
ported. 149 patients (mean age 46 yrs) had PTC in
TNM stages I-IV in 58%, 26%, 15% and 1% re-
spectively. Total thyroidectomy and remnant 131I
ablation (43%) were carried out in TNM high-risk
patients (stages III and IV) and in low-risk patients
(I and II) at risk for a (curable) recurrence (stages
pN1 and/or pT4). Hemi- or total thyroidectomy,
without radioiodine, was used in 76% of pT1-3 N0
tumours (68%). Central and/or lateral lymph-
adenectomy was performed in 42% of patients
(electively in the last 4 years). The mean follow-up
was 7 years. Results: 6 patients died of PTC and
8/143 patients treated for cure had a recurrence (6
nodal, 1 contralateral, 1 local). In low-risk patients
– including 68% of patients aged ≥45 yrs – the
cause specific 25-year survival rate was 100%, vs.
62% (at 15 years) (p <0.0001) in high-risk patients.
In stage I and stage II the recurrence-free survival
rates at 25 years were 95% and 100% respectively.
Risk factors for recurrence were macroscopic (p
<0.0001) but not microscopic local invasion (pT4);
stage pN1 (p = 0.0004). Only 1/107 patients ini-
tially judged node-negative had a nodal recur-
rence. FTC (n = 115; mean age 56 yrs; mean fol-
low-up 8 yrs): Cause-related death (n = 8) or seri-
ous recurrence (n = 3) occurred in 10/53 grossly
invasive FTC, in 1/45 minimally invasive FTC
with vascular invasion, and in none of 17 FTC with
capsular invasion (CI) alone, under radical treat-
ment (131I) in 75%, 33%, and 12% respectively. 20-
year disease-free survival in grossly and in mini-
mally invasive FTC was 78% and 95.5% respec-
tively (p = 0.0007). Patients aged <45 yrs and pa-
tients with minimally invasive FTC with CI alone
(all ages) had 100% 20-year disease-free survival
vs. 80% (p = 0.013) in the remainder. There was
no curable recurrence in FTC. The ratio of grossly
invasive FTC decreased (p <0.0001) during the
study period. 
Conclusions: 
– Risk-0 groups may be defined and selected for
a reduced extent of treatment (PTC pT1-3 N0;
FTC <45 yrs, or CI alone). 
– Older (≥45 yrs) patients with PTC in stages I
and II have an excellent prognosis (risk 0). 
– With selective (therapeutic) lymphadenectomy
the risk of nodal recurrence may be very low in
node negative tumours, without use of radioio-
dine. Meticulous lymphadenectomy is indicated
in pN1 tumours with nodal recurrences despite
131I (5/36 patients). 
– The technique of capsular dissection for extra-
capsular total uni- or bilateral thyroidectomy
provides excellent oncological and surgical re-
sults.
– A decrease in the incidence of FTC parallels a
decrease in endemic goitre in Switzerland. 
Keywords: papillary thyroid cancer; follicular thyroid
cancer; selective therapy; prognostic TNM classification;
capsular dissection; 25-year follow-up
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Summary 
Introduction
useful for defining low-risk and high-risk patients;
less appropriate systems do not consider age [16,
17], albeit the most important prognostic factor.
On the basis of prognostic classification, treatment
results may be compared and patients selected for
a risk-related scale of treatment. Selective treat-
ment is now widely considered appropriate [1, 2,
6, 7, 12, 14, 18, 19–23]. In low-risk patients with
PTC adequate treatment should also prevent (cur-
able) recurrences, which are most frequent in tu-
mours with nodal (pN1) or locally invasive (pT4)
disease at diagnosis [5, 21]. 
This study of 149 patients with PTC and 115
patients with FTC from one institution over a pe-
riod of 25 years confirms that low-risk patients can
be defined in whom no tumour-related deaths and
very few curable recurrences are observed after se-
lective risk-dependent therapy. 
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Patients and methods 
A total of 264 unselected consecutive patients with
DTC were treated and followed up from 1974 to 1999.
The records of 166 patients described previously [19] have
been updated. Clinical and diagnostic aspects have been
reported recently [20]. The patients were operated on by
one surgeon (E.G.) or with his assistance. The histopatho-
logical assessment was conducted prospectively by one
pathologist (Ph.U.H.) and his staff according to the WHO
classification [13, 19]. PTC were classified according to
the age-related prognostic TNM-classification system
[24] (Table 1). Extrathyroidal (pT4) PTC were subdivided
into gross invasion based on macroscopic intraoperative
evidence (pT4 ma), and thyroid capsular penetration as a
microscopic finding only (pT4 mi). Follicular carcinomas
(FTC) were classified as minimally or grossly invasive [3,
4, 13]; minimally invasive FTC were subdivided into those
with vascular invasion (VI), and those with exclusively cap-
sular invasion (CI) [10, 13]. 
The treatment strategy consisted in a restricted in-
terventional approach in selected low-risk patients [19,
20]1. 120/264 (45%) patients underwent total thyroidec-
tomy with radioiodine. Total thyroidectomy (n = 184) was
achieved in 62 patients (34%) by completion thyroidec-
tomy, after definitive histological diagnosis. Some patients
(7%) refused completion total thyroidectomy or use of ra-
dioactive iodine, as proposed by the therapeutic scheme.
Up to 1995 lymphadenectomy was performed for macro-
scopically involved nodes (selective therapeutic lymph-
adenectomy). From 1996 an elective routine (diagnostic,
prophylactic) lymphadenectomy of the central compart-
ment was introduced for pre- or intraoperatively con-
firmed PTC [25]. Technically complete extracapsular (no
subtotal or near total) lobar excision was performed by
capsular dissection [20, 26, 27] on the side of a suspicious
or carcinomatous nodule. 
261/264 patients were followed up 0,5–25 years.
Mean follow-up was 7 years (median 6) for PTC, and 8
years (median 7) for FTC. 14 patients had died from
thyroid carcinoma and 28 from unrelated causes without
tumour manifestation. 10 patients had been lost since the
last follow-up. 
Data analysis 
For statistical analyses the programs Stat View 4.51
(Abacus Concepts, Inc.) and SPSS for Macintosh Release
6.1.1 were used. Continuous variables are presented as
mean ± standard deviation and were analysed using the
Mann-Whitney test. Nominal variables are presented as
number of patients (%) and were compared using the chi-
square test or Fisher’s exact test when appropriate. 
Late results were analysed using the method of
Kaplan and Meier. 
Survival curves were compared using the log-rank
test. The effect of tumour diameter on survival curves was
analysed using Cox regression. P-values below 0.05 are
considered significant.
1 hemi- or total
thyroidectomy for
(a) PTC pT1,2,[3] N0,
(b) minimally inva-
sive FTC pT1,2 age
<45 yrs, or CI
alone; total thy-
roidectomy and
131I remnant abla-
tion for (a) pT4 and
pN1 PTC, (b)
grossly invasive
FTC and minimally
invasive FTC age
≥45 yrs
Stage age <45 years age ≥45 years 
I pT1-4 N0,1 M0 pT1 N0 M0
II pT1-4 N0,1 M1 pT2-3 N0 M0
III pT4 N0 M0
pT1-4 N1 M0
IV pT1-4 N0,1 M1
Table 1 
Age-related TNM
classification system. 
From UICC [24]. pT1:
<1cm; pT2: >1–4 cm;
pT3: >4 cm; pT4: ex-
tends beyond gland;
N1: regional lymph
node metastasis; M1:
distant metastasis. 
Results
During the study the ratio of PTC increased
from 35% to 66% (p = 0.03), whereas that of
grossly invasive FTC decreased from 41% to 9%
(p <0.0001) [20]. A concomitant benign nodular
goitre was more frequent in patients with a grossly
invasive FTC than in PTC (45% vs. 18%; p =
0.002); the same was true for nodular goitre with
functional autonomy (19% vs. 3%; p = 0.0007)
[20]. 
Papillary carcinoma 
Age groups
68/149 patients (46%) were in the young (<45
yrs) and 81 (54%) in the older age group (≥45 yrs).
N1-status (27%) was more common in young than
in older patients (35% vs. 20%; p = 0.033), and 
in pT4 than in pT1-3 tumours (65% vs. 17%; p
<0.0001). A pT4 tumour (21%) was found in 18%
of young and 23% of older patients (p = ns); gross
extrathyroidal invasion was present in 9%. 
M1 status
All patients with haematogenous metastases
(7/149; 5%) had extensive nodal disease (pN1), 5
patients had a pT4 tumour. 5/68 (7%) young pa-
tients had diffuse pulmonary radioiodine uptake
on the post-remnant ablation scan, and in 2/81
older patients (2.5%) pulmonary metastases were
seen on preoperative chest radiography.
TNM risk groups
86 (58%), 38 (26%), 23 (15%) and 2 (1%) pa-
tients were in the TNM risk groups I, II, III and
IV respectively, resulting in a low- (I + II) and a
high- (III + IV) risk population of 84% vs. 16%. In
low- and high-risk patients respectively, extrathy-
roidal invasion (pT4), nodal involvement, and dis-
tant disease at primary therapy were present in 12
(10%) vs. 19 (76%), (p <0.0001); 24 (19%) vs. 16
(64%), (p <0.0001), and 5 (4%) vs. 2 (8%), (p = ns). 
Follicular carcinoma
53 patients (46%) had a high-risk (grossly in-
vasive) and 62 patients (54%) a low-risk (mini-
mally invasive) FTC. The ratio has changed to
25% high-risk and 75% low-risk patients (p =
0.0003) since 1995, due to the declining rate of
grossly invasive FTC. 17 (27%) of minimally in-
vasive FTC had capsular invasion alone. On the
average, grossly invasive FTC were 1.6 cm larger
in diameter than minimally invasive FTC (p
<0.0001), and the patients were 15 years older (p
<0.0001). 4 patients (3.5%) had nodal disease and
1 (0,9%) had pulmonary metastases on the initial
chest x-ray. 
Node staging, lymphadenectomy
In 62/149 of patients with PTC (42%), and in
15/115 with FTC (13%), central and/or lateral
lymphadenectomy was performed, with pN1 status
in 27% of PTC and 3,5% of FTC. Absence of node
metastases was based on macroscopic appearance
(cN0), without lymphadenectomy, in 58% and
87% respectively. Elective vs. selective lym-
phadenectomy (PTC) resulted in a significant in-
crease of pN0 status (p = 0.03) and a non-signifi-
cant increase of N1 status [20, 25]. 
Treatment results by risk groups
Papillary carcinoma (n = 146, follow-up ≥0.5 yr)
20/24 (83%) of TNM high-risk and 43/122
(35%) of TNM low-risk patients had total thy-
roidectomy and radioiodine (p <0.0001) (Table 2).
All 6 patients who died from carcinoma were in the
TNM high-risk category, including 3 patients with
non-curative primary treatment. In 8/143 patients
a recurrence (1 contralateral, 1 local, and 6 nodal)
developed 1–8 years following primary treatment
for cure, resulting in death in 3 of the 4 TNM
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Treatment TNM stage total TNM
I II III IV low risk high risk
Hemithyroidectomy 26a 8 3c 0 37 (25%) 34 3 
Total thyroidectomy 32b 13 1 0 46 (32%) 45     
(65%)
1     
(17%)
Total thyroidectomy, 131I 26b 17 18b, c 2c 63 (43%) 43 (35%) 20 (83%)
Total 84 38 22 2 146 122 (84%) 24 (16%)
Postoperative events: 
curable recurrences (n = 5), (occurring 1–3 years after primary therapy):
a contralateral (n = 1) (pT2aN0)
b nodal (n = 4) (1pT2N0, 2pT4N1 [stage I]; 1pT1N1 [stage III])
deaths (n = 6) (occurring 1/2 –16 years after primary therapy):
c (1pT4N0, 3pT3,4N1, 2pT4N1M1)
Table 2
Papillary thyroid
carcinoma (n = 146).
Primary treatment
and outcome, 
by risk groups. 
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Figure 1
Late results of treat-
ment of PTC. 
a. Cause-specific sur-
vival in stages I-IV 
(I: solid line, open
circles; II: solid line,
closed circles; III:
broken line, +; IV:
dotted line, +).
b. Disease-free sur-
vival in TNM low-risk
(solid line) and high-
risk (broken line)
groups.
c. Recurrence-free
survival of patients
treated for cure in
TNM low-risk (solid
line) and high-risk
(broken line) groups.
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} }
high-risk and in none of the 4 TNM low-risk pa-
tients. Thus, there were 5 curable recurrences
(Table 2). Only 1/107 nodal recurrence was ob-
served in patients with a primary node negative tu-
mour, vs. 5/36 with a pN1 tumour (p = 0.0004, log-
rank test). In 3/83 patients without radical initial
therapy a postoperative event occurred (1 death; 
2 curable recurrences, 1 contralateral, 1 nodal).
Late results of treatment of PTC are plotted
by TNM risk groups in Figure 1. In low-risk pa-
tients the cause-specific 25-year survival rate and
the disease-free survival rate was 100% and 96.5%
respectively, vs. 62% and 59% (at 15 years) respec-
tively in high-risk patients (p <0.0001). Age ≥45 yrs
vs. <45 yrs significantly influenced survival (p =
0.01), but not disease-free and recurrence-free sur-
vival (Table 3). Macroscopic (pT4 ma), but not mi-
croscopic extrathyroidal invasion was a significant
risk factor for outcome in the entire series (p
<0.0001), and for recurrence in the low risk (TNM
I and II) group (p = 0.0002). Stage pN1 vs. N0 had
a significant impact on outcome. Gender, hemi-
thyroidectomy vs. total thyroidectomy, or use vs.
non-use of 131I did not influence the results. 
Follicular carcinoma
The risk-dependent treatment and the late re-
sults are shown in Table 4. In minimally invasive
FTC 1/62 patient died, from pulmonary meta-
stases from 12 years after total thyroidectomy. 3/53
patients with grossly invasive FTC died 2-7 years
after non-curative primary treatment, and 7 fur-
ther patients developed a serious recurrence lead-
ing to death in 4 patients 6-12 years after primary
treatment; the remaining 3 patients are living with
disease 4-8 years after radical treatment. Patients
with an adverse outcome (11/115) were aged 55-
80 (mean 71) years. 
The disease-free survival for minimally and 
for grossly invasive FTC are plotted in 
Figure 2a. Patients aged <45 yrs or those with CI
alone had cumulative survival and disease-free sur-
vival of 100% (Fig. 2b, Table 5). In univariate risk
factor analyses grossly invasive tumour, stage pT4,
nodal involvement, and tumour size had an adverse
effect on survival and/or disease-free survival
(Table 6). The adverse effect of 131I clearly reflects
patient selection.
Surgical morbidity
One patient, an 83-year-old man (0.4%) died
of cardiac failure after operation for a large infil-
trating papillary carcinoma. 5/264 patients (1.9%)
developed permanent hypoparathyroidism, repre-
senting 3% of those with total thyroidectomy.
Unilateral recurrent-nerve paralysis developed in
4 patients (1.5%) or in 1% of nerves at risk (n =
407). Seven of the 8 patients with morbidity had a
concomitant recurrent benign goitre, completion
total thyroidectomy, extensive central nodal in-
volvement, or a grossly invasive FTC respectively.
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Figure 2
Late results of treat-
ment of FTC.
a. Disease-free sur-
vival of patients with
minimally invasive
(solid line) and with
grossly invasive
(broken line) FTC.
b. Disease-free sur-
vival of patients with
CI alone or age 
<45 years (solid line)
compared to remain-
ing patients (broken
line) with FTC.
a
b
Variable survival disease- recurrence-
free survival free survival
TNM high risk vs. low risk <0.0001 <0.0001 0.0025
Age ≥45 vs. <45 0.01 ns ns
Stage T4 vs. T1-3 <0.0001 <0.0001 0.008
Stage T4 macroscopic vs. <0.0001 <0.0001 <0.0001
T1-3, T4 microscopic
Stage N1 vs. N0 0.001 <0.0001 0.006
Stage M1 vs. M0 0.008 0.009
Ø cm 0.001 0.005 ns 
Table 3 
Risk factors in PTC 
(n = 146) by uni-
variate analysis.
Treatment minimally invasive (n = 62) grossly invasive total
capsular invasion alone (n = 17) vascular invasion (n = 45) (n = 53)
Hemithyroidectomy 10 
88%
26 
67%
5 
25%
41
50%
Total thyroidectomy 5 4a 8a 17
Total thyroidectomy, 131I 2 (12%) 15 (33%) 40b, c (75%) 57 (50%)
Total 17 45 53 115
Postoperative events (n = 11): deaths (n = 8): a 1 death; b 6 deaths; c serious recurrence (n = 3)
Table 4 
Follicular thyroid 
carcinoma (n = 115).
Primary treatment
and outcome, by risk
groups (no of 
patients [%]).
} } } }
This study has the advantages of precise
prospective documentation and uniform condi-
tions with respect to surgery and pathology. The
duration of follow-up was relatively short, due to
an increasing number of annually referred pa-
tients. However, though late deaths may occur [9],
curable recurrences and those heralding an un-
favourable course are seen most frequently during
the first 5–10 years [5, 9, 21, 22] – 1–8 years in our
16/255 patients with primary therapy for cure. 
During the 25-year period the proportion of
FTC decreased significantly, from 65% to 34% of
all DTC, due to a decrease in grossly invasive
FTC. Therefore, PTC became the most frequent
tumour. For the 30-year period 1944–1973 a de-
crease in FTC from 52% to 38% was found in a
series of 550 pathological specimens of thyroid
carcinoma in Switzerland [28]. These data reflect
a continuous decrease in the incidence of FTC,
which parallels a decrease in the prevalence of sim-
ple goitre [29] and of its toxic nodular variant [30]
over decades in Switzerland. 
Our results confirm that the prognostic classi-
fication of FTC on the basis of invasiveness is valid.
The outcome was unfavourable in 10/62 patients
with grossly invasive FTC, in 1/45 minimally in-
vasive FTC with VI, and in none of the 17 mini-
mally invasive FTC with CI alone. The cause-spe-
cific disease-free survival rates at 20 years were
78% for grossly invasive and 95.5% for minimally
invasive FTC (p = 0.0007). In agreement with De
Groot et al. [9], no curable recurrence was ob-
served in FTC. No adverse outcome was noted in
young (<45 yrs) patients and – independently of the
patient’s age – in tumours with CI alone (mean age
54 yrs). Nodal involvement (3.5%) was clinically
and intraoperatively obvious, and no metachro-
nous nodal disease occurred. Routine lymph-
adenectomy is therefore not indicated in FTC [1,
4, 12, 14]. Multifocal and contralateral involve-
ment (7%) was grossly evident and led to total thy-
roidectomy. Our results are in agreement with
studies where subgroups without deaths [9, 10] or
with near 100% survival rates [11, 31] were noted,
or in which hemithyroidectomy vs. total thy-
roidectomy did not adversely influence survival or
recurrence [11, 12]. 
In definable patients without risk of systemic
disease complete removal of the local tumour tis-
sue by total primary hemithyroidectomy or total
thyroidectomy is essential, whereas remnant abla-
tion does not appear rational. Follicular neoplasia
(as evidenced by high cellularity on fine needle as-
piration biopsy) [32] should be treated by diag-
nostic primary hemithyroidectomy, avoiding ipsi-
lateral reoperation with its increased morbidity
and potentially incomplete local tumour excision
[20, 22]. 
For PTC the multivariate age-related TNM
classification [24] proved to be valuable for defin-
ing low-risk (stages I and II) and high-risk (stages
III and IV) patients, with significantly different
rates of survival (100% vs. 62% at 15 years; p
<0.0001), disease-free survival (97% vs. 59%; p
<00001), and recurrence-free survival (i.e. after
primary treatment for cure) (96.5% vs. 80%; p =
0.0025). Treatment strategy was radical treatment
in high-risk patients and in those low-risk patients
at risk for curable recurrence (N1 or T4 status) [4,
5, 14, 16, 21, 23, 25, 33]. Our results confirm the
impact of age on survival: young (<45 yrs) patients
had a mortality rate of 0% in spite of stage T4 in
18%, N1 in 35%, and M1 in 7%. The same tumour
characteristics determine a much less favourable
outcome in older, i.e. high-risk patients. However,
in the absence of these characteristics, i.e. in pT1-
3 N0 M0 tumours, older patients belong to the low-
risk category and have an excellent prognosis, with
no deaths and even with no instance of a curable
recurrence in our study. Stages I and II did not have
a significantly different prognosis, thus confirming
the data of Hundahl et al. [8]. These authors men-
tion the ”opportunity for simplifying the current
TNM prognostic system further”. Our results in-
dicate that a reduced scale of treatment may be ad-
equate for pT1-3 N0 tumours, independently of the
patient’s age. In this subset (66% of all PTC) no
death occurred, and there was only 1/36 con-
tralateral recurrence after hemithyroidectomy and
only 1/107 nodal recurrence in patients without
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Survival minimally grossly CI alone or 
invasive invasive patients <45 yrs
5 yr 100% (35) 96% (42) 100% (27)
10 yr 100% (15) 85% (29) 100% (11)
20 yr 92% (4) 81% (3) 100% (3)
Table 5
Cause-specific survival rates in subgroups of FTC.
( ) = patients at risk.
Variable survival disease-free 
survival
Grossly vs. minimally invasive ns 0.0007
tumour 
T4 vs. T1-3 <0.0001 <0.0001
N1 vs. N0 <0.0001 <0.0001
Ø cm ns 0.05
Use of 131I vs. no 131I ns 0.03
Hemithyroidectomy vs. total ns ns
thyroidectomy
Table 6
Risk factors in FTC by univariate analysis.
Discussion
initial nodal involvement (though 80% had no
lymphadenectomy, and 74% had no 131I). After
hemithyroidectomy, contralateral recurrences
were noted in 4% [6], and in 14% [5, 33] of low-
risk patients; several authors report very low rates
(0.9%–3%) [18, 21, 33] of nodal recurrence in pa-
tients who were initially node-negative without
use of radioiodine. In pT1-3 N0 tumours it has not
been shown that 131I ablation offers any advantage
in improving the already excellent results [16, 19].
On the other hand, radioiodine does not prevent
nodal recurrence in patients with initial node dis-
ease [5, 21, 22, 34, 35]. In low-risk patients with
primary lymph node metastases 131I is also indi-
cated for detection and treatment of diffuse pul-
monary metastases. Extensive nodal disease is a
marker for disseminated pulmonary disease [21,
22, 36], which was detected in 5 (7%) of our young
patients (21% of those with initial nodal disease)
on the post-ablation scan (none of these patients
developed a recurrence). In rare, anecdotal low-
risk patients with PTC a fatal outcome was re-
ported [37, 38]. These patients had gross invasive
nodal disease [38, 39].
The question arises how radical lymph-
adenectomy is to be performed for detection of
(occult) nodal disease, adequate staging, and stage-
dependent treatment. Interestingly, no significant
increase in node positivity, and no influence on
therapeutic results were observed in our series with
routine vs. selective lymphadenectomy [25]. In one
report routine lymphadenectomy resulted in a
high incidence of N1 status (82%) and to im-
provement of survival and recurrence [35]. More
radical lymphadenectomy may itself improve ther-
apeutic results by stage migration [40]: occult N1
tumours are eliminated from the N0 group, and N1
groups are enlarged with more favourable tumours
with only occult nodal disease (Will Rogers phe-
nomenon) [40, 41]. In sum, the impact of elective
(prophylactic) node dissection on outcome re-
mains uncertain [25]. 
In some apparently intrathyroidal tumours the
pathologist may document penetration of the thy-
roid capsule. We classified these tumours as stage
pT4. Woolner et al. [3, 4] classified only tumours
with gross local infiltration as “extrathyroidal”
(10%; 9% in our series), without however detract-
ing from the excellent outcome in the “intrathy-
roidal” and ”occult” (i.e. pT1-3) categories. Ac-
cordingly, in our patients only macroscopic, but
not microscopic penetration significantly influ-
enced outcome. Special therapeutic measures such
as external percutaneous irradiation are not war-
ranted on the basis of microscopic penetration
only. 
Our study confirms that it is possible to select
patients with FTC or PTC who require radical
therapy, and those in whom technically correct
hemithyroidectomy or total thyroidectomy with-
out remnant ablation provides a virtually perfect
prognosis. In PTC prognostic classification sys-
tems may accurately segregate low and high risk
for death, but TNM stages I and II englobe an in-
homogeneous population with respect to recur-
rence; N1 and/or T4 status are indicators for radi-
cal therapy in young patients with PTC. For clin-
ical PTC without nodes we prefer total to
hemithyroidectomy, to eliminate the problem of
potential contralateral recurrence. However, some
patients feel invalidated by loss of a vital organ and
prefer hemithyroidectomy with acceptance of low
risk of curable contralateral recurrence. We also
favour routine (prophylactic) central lymph node
dissection [1, 20, 21, 33], but the possible advan-
tages should not be compromised by damage to the
parathyroids or recurrent laryngeal nerves. In 0-
risk patients cure of disease should not be com-
promised by postoperative iatrogenic disease (ex-
ogenous hyperthyroidism for TSH suppression)
or excessive follow-up measures [1, 2, 6, 14, 23]. 
Are the surgeon’s tactics and technique prog-
nostic factors [37]? Capsular dissection [26, 27,
42], with fine preparatory technique is essential (a)
for low morbidity in thyroid surgery [43], and (b)
for oncological adequacy [20]. The technique was
first used by Kocher [44, 45], who deliberately op-
posed it to a less subtle and anatomically different
operative practice [44]; hence variance in operative
technique is still of concern [27, 46]. Incomplete
tumour resection may result in a fatal outcome
even in low-risk patients [37, 47]. 
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